MX2017008410A - Reduccion selectiva de residuos cisteina en anticuerpos il-17. - Google Patents
Reduccion selectiva de residuos cisteina en anticuerpos il-17.Info
- Publication number
- MX2017008410A MX2017008410A MX2017008410A MX2017008410A MX2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- secukinumab
- preparation
- antigen binding
- binding fragments
- Prior art date
Links
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 229960004540 secukinumab Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 238000005251 capillar electrophoresis Methods 0.000 abstract 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 abstract 1
- 238000005341 cation exchange Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a métodos para reducir selectivamente CysL97 en una preparación de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (p. ej., una preparación de anticuerpos secukinumab), que ha sido producida de forma recombinante por células de mamíferos. También se proporcionan preparaciones purificadas de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos producidos por estos métodos, p. ej., preparaciones purificadas de secukinumab, en donde el nivel de anticuerpos IL-17 intactos o fragmentos de unión a antígeno de los mismos (p. ej., secukinumab) en la preparación es alto, p. ej., al menos aproximadamente 90%, tal como se mide mediante electroforesis capilar con dodecil-sulfato de sodio (CE-SDS) y en donde el nivel de actividad de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (p. ej., secukinumab) en la preparación es alta, p. ej., al menos aproximadamente 92%, tal como se mide mediante cromatografía de intercambio catiónico (CEX).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095361P | 2014-12-22 | 2014-12-22 | |
| PCT/IB2015/059824 WO2016103146A1 (en) | 2014-12-22 | 2015-12-21 | Selective reduction of cysteine residues in il-17 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008410A true MX2017008410A (es) | 2017-10-19 |
Family
ID=55135470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008410A MX2017008410A (es) | 2014-12-22 | 2015-12-21 | Reduccion selectiva de residuos cisteina en anticuerpos il-17. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11292833B2 (es) |
| EP (2) | EP4389143A2 (es) |
| JP (3) | JP7021950B2 (es) |
| KR (2) | KR20230159617A (es) |
| CN (4) | CN114316044A (es) |
| AR (1) | AR103172A1 (es) |
| AU (1) | AU2015370515B2 (es) |
| BR (1) | BR112017010069A2 (es) |
| CA (1) | CA2971541A1 (es) |
| IL (2) | IL298761A (es) |
| MX (1) | MX2017008410A (es) |
| PH (1) | PH12017500967A1 (es) |
| RU (2) | RU2765307C2 (es) |
| SG (1) | SG11201703639QA (es) |
| WO (1) | WO2016103146A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041533A1 (en) | 2016-11-07 | 2018-05-11 | Seattle Genetics, Inc. | Distribution of engineered-cysteine caps |
| WO2020037016A1 (en) * | 2018-08-15 | 2020-02-20 | Bristol-Myers Squibb Company | Protein fragmentation control strategy by re-oxidation in downstream chromatography |
| CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
| EP4255927A1 (en) * | 2020-12-02 | 2023-10-11 | Fresenius Kabi Deutschland GmbH | Methods of selectively reducing antibodies |
| CA3205650A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766205A (en) | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| JP3610395B2 (ja) * | 1991-08-26 | 2005-01-12 | 敏一 中村 | 成熟肝実質細胞増殖因子 |
| CZ20032208A3 (cs) | 2001-02-23 | 2004-01-14 | Immunex Corporation | Zvýšený výtěžek aktivních proteinů |
| US20050123532A1 (en) * | 2001-12-04 | 2005-06-09 | Takaharu Kouno | Method of activating protein |
| DE60327715D1 (de) | 2002-12-20 | 2009-07-02 | Mitsubishi Tanabe Pharma Corp | Verfahren zum schutz von thiolgruppen in antikörpern |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
| EP1893632B1 (en) * | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
| JP5364382B2 (ja) | 2006-02-07 | 2013-12-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 遊離チオール部分を有するタンパク質の安定化された組成物 |
| LT3327026T (lt) | 2007-07-09 | 2019-11-11 | Genentech Inc | Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu |
| US20110033378A1 (en) | 2008-01-18 | 2011-02-10 | Medlmmune, Llc. | Cysteine Engineered Antibodies For Site-Specific Conjugation |
| PL2896404T3 (pl) * | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| KR101620771B1 (ko) | 2010-10-08 | 2016-05-12 | 노파르티스 아게 | Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 |
| AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| JP5782279B2 (ja) | 2011-01-20 | 2015-09-24 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法および基板処理装置 |
| EP3674320A3 (en) | 2011-10-27 | 2020-08-12 | Genmab A/S | Production of heterodimeric proteins |
| AU2012341081B2 (en) * | 2011-11-21 | 2015-06-04 | Novartis Ag | Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
-
2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/es unknown
- 2015-12-21 KR KR1020237038206A patent/KR20230159617A/ko active Application Filing
- 2015-12-21 BR BR112017010069A patent/BR112017010069A2/pt not_active Application Discontinuation
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/es unknown
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/zh active Pending
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/zh active Active
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/ru active
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/zh active Active
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/ja active Active
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/zh active Active
- 2015-12-21 EP EP24170348.7A patent/EP4389143A2/en active Pending
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en active Application Filing
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/ko active IP Right Grant
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/ru active
-
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
-
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/ja active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
-
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500967A1 (en) | Selective reduction of cysteine residues in il-17 antibodies | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| WO2016130704A3 (en) | Methods and compositions for analyzing cellular components | |
| MY192561A (en) | Taurine supplemented cell culture medium and methods of use | |
| MX2020012327A (es) | Anticuerpo antagonista de cd73. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
| MX2018000897A (es) | Celulas madre hematopoyeticas que expresan pd-l1 y usos. | |
| MX2017013949A (es) | Composiciones mectantes a base de seda y sus metodos. | |
| BR112019003361A2 (pt) | métodos e usos de frações de material orgânico dissolvido para ligação a íons metálicos | |
| BR112018001511A2 (pt) | ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano | |
| MX2022011973A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| IN2015DN03206A (es) | ||
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| BR112015014718A2 (pt) | métodos de uso de cromatografia de troca iônica para controlar níveis de glicoformas ricas em manose | |
| MA40371A (fr) | Sélectivité efficace des protéines recombinées | |
| MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
| NZ742210A (en) | Neospora vaccine composition | |
| MX2019015499A (es) | Método para producir d-psicosa a partir de un complejo de borato y d-psicosa usando cromatografía y composición que contiene d-psicosa. |